Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial

[1]  T. Himeno,et al.  Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions , 2019, Journal of diabetes investigation.

[2]  Akshay S. Desai,et al.  Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. , 2015, European heart journal.

[3]  R. Klein,et al.  The clinical implications of recent studies on the structure and function of the retinal microvasculature in diabetes , 2015, Diabetologia.

[4]  R. Pop-Busui,et al.  Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials , 2014, Current Diabetes Reports.

[5]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[6]  J. Albers,et al.  Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[7]  M. Woodward,et al.  Risk prediction models: II. External validation, model updating, and impact assessment , 2012, Heart.

[8]  R. Freeman,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[9]  Roger Newson,et al.  Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .

[10]  J. Fleg,et al.  Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial , 2010, Diabetes Care.

[11]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: validating a prognostic model , 2009, BMJ : British Medical Journal.

[12]  S. Solomon,et al.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Pop-Busui,et al.  Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort , 2009, Journal of the peripheral nervous system : JPNS.

[14]  E. Feldman,et al.  Diabetic neuropathy: mechanisms to management. , 2008, Pharmacology & therapeutics.

[15]  N. Chaturvedi,et al.  Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe , 2008, Diabetes Care.

[16]  Michael W Kattan,et al.  Validating a prognostic model , 2006, Cancer.

[17]  R. Klein,et al.  Abnormalities of Retinal Microvascular Structure and Risk of Mortality From Ischemic Heart Disease and Stroke , 2006, Hypertension.

[18]  H. Sone,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[19]  M. Davidson.  Current information for better diabetes care , 2001 .

[20]  P. Sönksen,et al.  Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. , 2000, Journal of clinical epidemiology.

[21]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[22]  L. Groop,et al.  Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4 , 1998, Diabetologia.

[23]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.

[24]  M. Özkaya,et al.  Action to Control Cardiovascular Risk in Diabetes , 2013 .